Wednesday 12th June, 16:15–17:45, Hall 6, IFEMA – Feria de Madrid, Madrid, Spain.
Chairs – John Isaacs and Thomas Dörner
- What to choose: a second TNFI or an alternative class of biologic for patients with JIA who have failed their first TNF. Lianne Kearsley-Fleet
- Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. Bernard Combe
- More on this topic: Quick guide | JAK inhibitors in RA: A round-up of the phase III trials
- Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Oliver Distler
- More on this topic: News story | Nintedanib slows lung function decline in SSc-associated interstitial lung disease
- MiR-34A is a potential therapeutic target in osteoarthritis. Mohit Kapooor
- A systematic review and meta-analysis assessing gastrointestinal, liver, renal and cardiovascular adverse events of paracetamol. Jaspreet Kaur
- More on this topic: News story | Findings question the use of acetaminophen for pain relief in OA patients
- Less is more: analysing the impact of repeated antinuclear antibody testing. Ai Li Yeo
- Predicting severe infection in repeat cycles of rituximab and effects of hypogammaglobulinaemia for the treatment of rheumatic and musculoskeletal diseases. Md Yuzaiful Md Yusof
- More on this topic: News story | Serious infection risk similar among non-TNF inhibitor biologics in RA
- Do MRI-detected erosions in patients with clinically suspect arthralgia predict progression to rheumatoid arthritis? A longitudinal study. Fenne Wouters
- Randomised, double-blind, placebo-controlled, multiple-dose, Phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis. Philip Mease